Allergan plc (NYSE: AGN) agreed to buy Tobira Therapeutics Inc. (Nasdaq: TBRA) for as much as $1.7 billion to gain a late-stage experimental drug to treat liver diseases, one of the most anticipated categories in biotechnology.

Allergan recently agreed to buy Vitae Pharmaceuticals Inc. (Nasdaq: VTAE), after the company terminated its merger with Pfizer Inc. (NYSE: PFE). In other pharmaceutical deal, Sunovion Pharmaceuticals Inc. is acquiring Cynapsus Therapeutics Inc. (Nasdaq: CYNA).

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.